Actinium Pharmaceuticals

Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.
Type
Public
HQ
New York, US
Founded
2000
Size (employees)
18 (est)+50%
Actinium Pharmaceuticals was founded in 2000 and is headquartered in New York, US

Actinium Pharmaceuticals Office Locations

Actinium Pharmaceuticals has office in New York
New York, US

Actinium Pharmaceuticals Metrics

Actinium Pharmaceuticals Summary

Market capitalization

$80.3 M

Closing share price

$1.42
Actinium Pharmaceuticals's current market capitalization is $80.3 M.

Actinium Pharmaceuticals Market Value History

We estimate that Actinium Pharmaceuticals's current employees are approximately 9% female and 91% male.

Actinium Pharmaceuticals Online Presence

Actinium Pharmaceuticals Company Life

You may also be interested in